Recursion Pharmaceuticals, Inc. (RXRX) Earnings
Recursion Pharmaceuticals, Inc. is expected to report next earnings on November 4, 2026 (in NaN days), with a consensus EPS estimate of $-0.23. RXRX has beaten EPS estimates in 5 of its last 12 reported quarters (average surprise +13.2% over the last four).
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| Aug 5, 2026 | $-0.24 | $-0.25 | -4.2% | $7M | -33.4% |
| May 6, 2026 | $-0.30 | $-0.22 | +26.7% | $6M | -60.1% |
| Feb 25, 2026 | $-0.28 | $-0.21 | +25.0% | $36M | +86.4% |
| Nov 5, 2025 | $-0.38 | $-0.36 | +5.3% | $5M | -78.9% |
| Feb 28, 2025 | $-0.44 | $-0.53 | -20.5% | $5M | -76.3% |
| Aug 8, 2024 | $-0.35 | $-0.40 | -14.3% | $14M | +8.7% |
| May 9, 2024 | $-0.43 | $-0.39 | +9.3% | $14M | +9.0% |
| Feb 27, 2024 | $-0.46 | $-0.40 | +13.0% | $11M | -46.5% |
| Nov 9, 2023 | $-0.38 | $-0.43 | -13.2% | $10M | -50.8% |
| Feb 27, 2023 | $-0.15 | $-0.31 | -106.7% | $14M | -42.5% |
| Mar 23, 2022 | $-0.30 | $-0.38 | -26.7% | $3M | -58.6% |
| Nov 10, 2021 | $-0.28 | $-0.28 | +0.0% | $3M | -1.3% |
Source: company filings + earnings calendar. For informational purposes only — not investment advice.
Earnings call summary
Q2 FY2026 · August 5, 2026
AI summary of management’s prepared remarks and analyst Q&A. For informational purposes only — not investment advice.
Management highlights
- Core Strategic Focus * Recursion's central organizational priority is harnessing full AI capabilities to develop improved medicines for patients consistently and with urgency, with a focus on building a repeatable, AI-driven drug discovery engine that delivers assets from early discovery through clinical development. - Clinical Pipeline Progress * REC 1245, a potential first-in-class oncology program fully discovered via Recursion's AI platform, has demonstrated a well-tolerated safety profile with no dose-limiting toxicities observed to date, alongside an encouraging PK-PD profile. Additional data for this program is expected in the second half of 2026. * REC 4881, a candidate for familial adenomatous polyposis (FAP), a serious condition with no currently approved treatments, has already delivered strong proof of concept with meaningful and durable treatment impact. Recursion has initiated formal engagement with the FDA to discuss a potential registration pathway, with an update planned for the second half of 2026. * Rec4539, a best-in-class LSD1 inhibitor developed for small cell lung cancer and acute myeloid leukemia (AML), has dosed its first patient in a Phase 1 trial. This precision-designed molecule was engineered to address common class-limiting toxicities (such as thrombocytopenia) and offers potential improved safety and enhanced CNS penetration compared to existing agents in this class.
Guidance
No forward-looking financial or operational guidance, including any upward revisions, downward revisions, or maintained guidance, was provided in the released transcript excerpt.
Segment performance
No financial performance data for product segments was provided in the released transcript excerpt.
Risks & headwinds
No discussion of business risks, operational failures, or material emerging challenges was included in the released transcript excerpt.